AR042244A1 - EXPRESSION VECTOR, PROCEDURE FOR THE PREPARATION OF GENETIC HETEROLOGICAL PRODUCTS AND SELECTION PROCEDURE FOR HIGH PRODUCTION RECOMBINING CELLS - Google Patents

EXPRESSION VECTOR, PROCEDURE FOR THE PREPARATION OF GENETIC HETEROLOGICAL PRODUCTS AND SELECTION PROCEDURE FOR HIGH PRODUCTION RECOMBINING CELLS

Info

Publication number
AR042244A1
AR042244A1 ARP030104395A ARP030104395A AR042244A1 AR 042244 A1 AR042244 A1 AR 042244A1 AR P030104395 A ARP030104395 A AR P030104395A AR P030104395 A ARP030104395 A AR P030104395A AR 042244 A1 AR042244 A1 AR 042244A1
Authority
AR
Argentina
Prior art keywords
expression vector
procedure
cells
preparation
products
Prior art date
Application number
ARP030104395A
Other languages
Spanish (es)
Inventor
Jurgen Fieder
Enenkel Barbara Dr
Otto Ralf Dr
Grammatikos Stefanos Dr
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR042244A1 publication Critical patent/AR042244A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/69—Increasing the copy number of the vector

Abstract

Un vector de expresión para células eucarióticas que abarca un gen que codifica una proteína de interés, en enlace funcional con un promotor ubiquitina/S27a del hámster y un gen que codifica una proteína fluorescente. Preferiblemente, el vector de expresión contiene, además, un gen marcador de la selección amplificable. Se describen, además, células huésped transfectadas con el vector de expresión, preferiblemente células de mamífero, procedimientos para la preparación de productos génicos heterólogos y un procedimiento para la selección de células de alta producción. Reivindicación 7: Vector de expresión según una de las reivindicaciones 1 a 6, caracterizado porque el gen marcador de la selección amplificable codifica dihidrofolato- reductasa (DHFR) o una proteína de fusión a base de la proteína fluorescente y DHFR. Reivindicación 8: Vector de expresión según una de las reivindicaciones 3 a 7, caracterizada porque el intensificador es un intensificador de CMV o SV40. Reivindicación 12: Célula huésped según la reivindicación 11, caracterizada porque se trata de una célula de mamífero, preferiblemente una célula CHO. Reivindicación 16: Procedimiento según la reivindicación 15, caracterizado porque la proteína heterómera es un anticuerpo.An expression vector for eukaryotic cells that encompasses a gene that encodes a protein of interest, in functional bond with a hamster ubiquitin / S27a promoter and a gene that encodes a fluorescent protein. Preferably, the expression vector also contains a marker gene of the amplifiable selection. In addition, host cells transfected with the expression vector, preferably mammalian cells, procedures for the preparation of heterologous gene products and a method for the selection of high-production cells are described. Claim 7: Expression vector according to one of claims 1 to 6, characterized in that the amplifiable selection marker gene encodes dihydrofolate reductase (DHFR) or a fusion protein based on fluorescent protein and DHFR. Claim 8: Expression vector according to one of claims 3 to 7, characterized in that the intensifier is an intensifier of CMV or SV40. Claim 12: Host cell according to claim 11, characterized in that it is a mammalian cell, preferably a CHO cell. Claim 16: Method according to claim 15, characterized in that the heteromeric protein is an antibody.

ARP030104395A 2002-11-29 2003-11-28 EXPRESSION VECTOR, PROCEDURE FOR THE PREPARATION OF GENETIC HETEROLOGICAL PRODUCTS AND SELECTION PROCEDURE FOR HIGH PRODUCTION RECOMBINING CELLS AR042244A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10256083A DE10256083A1 (en) 2002-11-29 2002-11-29 Expression vector, process for the production of heterologous gene products and selection process for high-producing recombinant cells

Publications (1)

Publication Number Publication Date
AR042244A1 true AR042244A1 (en) 2005-06-15

Family

ID=32403676

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104395A AR042244A1 (en) 2002-11-29 2003-11-28 EXPRESSION VECTOR, PROCEDURE FOR THE PREPARATION OF GENETIC HETEROLOGICAL PRODUCTS AND SELECTION PROCEDURE FOR HIGH PRODUCTION RECOMBINING CELLS

Country Status (12)

Country Link
EP (1) EP1567648A1 (en)
JP (1) JP2006507829A (en)
KR (1) KR100820035B1 (en)
CN (1) CN1717486A (en)
AR (1) AR042244A1 (en)
AU (1) AU2003292102A1 (en)
BR (1) BR0316510A (en)
CA (1) CA2507714A1 (en)
DE (1) DE10256083A1 (en)
MX (1) MXPA05005482A (en)
TW (1) TWI321152B (en)
WO (1) WO2004050879A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
JP5701061B2 (en) 2007-12-21 2015-04-15 ノバルティス アーゲー Mammalian expression vector
DK2401377T3 (en) 2009-02-27 2016-08-29 Novartis Ag Expression vector system comprising two selection markers
KR101239495B1 (en) * 2011-01-21 2013-03-05 경상대학교산학협력단 Recombinant adenovirus expressing αA-crystallin gene and gene therapy using the same for the prevention and treatment of retinal vascular diseases
WO2012161352A1 (en) * 2011-05-25 2012-11-29 国立大学法人岡山大学 Reic-expressing adenovirus vector
FR2981946B1 (en) * 2011-10-28 2015-02-20 Lfb Biotechnologies TRANSCRIPTION UNITS AND THEIR USE IN EXPRESSION VECTORS (YB2 / 0)
KR102288233B1 (en) 2013-07-31 2021-08-10 노파르티스 아게 Novel selection vectors and methods of selecting eukaryotic host cells
CN104404072B (en) * 2014-11-24 2018-04-27 浙江大学 Exogenous gene expression amount and the method for screening transgenic silkworm are predicted with marker gene
CN106442685B (en) * 2016-10-25 2019-03-26 山东大学 A kind of method of fast and low-cost screening protein expression condition
AU2020269597A1 (en) * 2019-05-07 2021-09-23 Amgen Inc. Vectors and expression systems for producing recombinant proteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) * 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
DE3584341D1 (en) 1984-08-24 1991-11-14 Upjohn Co RECOMBINANT DNA COMPOUNDS AND EXPRESSION OF POLYPEPTIDES LIKE TPA.
US5491084A (en) * 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
WO1995007463A1 (en) * 1993-09-10 1995-03-16 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
DE19539493A1 (en) * 1995-10-24 1997-04-30 Thomae Gmbh Dr K Strong homologous promoter from hamster
WO1998032869A1 (en) * 1997-01-29 1998-07-30 Neurosearch A/S Expression vectors and methods for in vivo expression of therapeutic polypeptides
DE60025829T2 (en) * 1999-07-12 2006-11-02 Genentech, Inc., South San Francisco EXPRESSION VECTORS AND APPLICATION METHODS
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid

Also Published As

Publication number Publication date
KR20050085203A (en) 2005-08-29
CN1717486A (en) 2006-01-04
TW200502388A (en) 2005-01-16
EP1567648A1 (en) 2005-08-31
KR100820035B1 (en) 2008-04-10
DE10256083A1 (en) 2004-08-12
MXPA05005482A (en) 2005-07-25
CA2507714A1 (en) 2004-06-17
AU2003292102A1 (en) 2004-06-23
JP2006507829A (en) 2006-03-09
WO2004050879A1 (en) 2004-06-17
BR0316510A (en) 2005-10-04
TWI321152B (en) 2010-03-01

Similar Documents

Publication Publication Date Title
US20210095323A1 (en) Method of producing biologically active vitamin k dependent proteins by recombinant methods
AR042244A1 (en) EXPRESSION VECTOR, PROCEDURE FOR THE PREPARATION OF GENETIC HETEROLOGICAL PRODUCTS AND SELECTION PROCEDURE FOR HIGH PRODUCTION RECOMBINING CELLS
EP0574402B2 (en) Expression of pace in host cells and methods of use thereof
ES2266159T3 (en) IMPROVEMENT OF GALACTOSILATION OF RECOMBINANT GLICOPROTEINS.
AR018023A1 (en) PROCEDURE FOR THE MANUFACTURE OF POLYPEPTIDES WITH APPROPRIATE GLYCOSILATION
JP4463988B2 (en) Method for producing factor VII
TW200732472A (en) Method for the recombinant expression of a polypeptide
ATE342275T1 (en) TEMPORARILY IMMORTALIZED CELLS FOR USE IN GENE THERAPY
AR024735A1 (en) STABLE FACTOR COMPOSITIONS VIII
Parcq et al. Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator A chain
Kaufman Use of recombinant DNA technology for engineering mammalian cells to produce proteins
Khorshidi et al. Functional expression of the human coagulation factor IX using heterologous signal peptide and propeptide sequences in mammalian cell line
WO2004084838A3 (en) Identification, quantification, and characterization of t cells and t cell antigens
KERBLAT et al. Importance of thioredoxin in the proteolysis of an immunoglobulin G as antigen by lysosomal Cys‐proteases
EA035444B1 (en) Production of fully processed and functional factor x in a furin-secreting mammalian expression system
Zhou et al. Presentation of cytosolic antigens via MHC class II molecules
JPWO2009048067A1 (en) Genetically modified blood coagulation factor X having no sugar chain and method for producing the same
US9587008B2 (en) Method of producing recombinant vitamin K dependent proteins
Satoh et al. Stable production of recombinant pro-urokinase by human lymphoblastoid Namalwa KJM-1 cells: host-cell dependency of the expressed-protein stability
Rosnoblet et al. Regulated von Willebrand factor (vWf) secretion is restored by pro-vWf expression in a transfectable endothelial cell line
Bahrami et al. Production of recombinant human factor IX by propeptide modification in Drosophila S2 cell line
Fitzgerald et al. Umbilical cord endothelial cells expressing large T antigen: comparison with primary cultures and effect of cell age
AU2016200807A1 (en) Method of producing biologically active vitamin K dependent proteins by recombinant methods
AU2013211534A1 (en) Method of producing biologically active vitamin K dependent proteins by recombinant methods
UY26907A1 (en) PROCESS TO PREPARE A NEUTROPHIL INHIBITING FACTOR

Legal Events

Date Code Title Description
FB Suspension of granting procedure